{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T12:35:29Z","timestamp":1721738129051},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T00:00:00Z","timestamp":1524182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent approaches in multiple myeloma (MM) treatment have targeted CD38. As antigen expression levels on plasma cells (PCs) were demonstrated to affect response to monoclonal antibody (mAb) treatment, a precise characterization of PC phenotype is warranted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Anti\u2010CD38 mAb (isatuximab) was tested for antibody\u2010dependent cellular cytotoxicity (ADCC) in MM cell lines. Quantification of the number of sites (NOS) of CD38 on bone marrow PCs and other immune cells obtained from light chain (AL) amyloidosis (<jats:italic>n<\/jats:italic>\u2009=\u200946) and smoldering multiple myeloma (SMM) patients (<jats:italic>n<\/jats:italic>\u2009=\u200919) was performed with two different quantitative flow cytometry (QFCM) applications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ADCC activity of isatuximab was observed in cell lines with &gt;100 \u00d7 10<jats:sup>3<\/jats:sup> CD38\u2010NOS only. The average PC CD38\u2010NOS was 153\u2009\u00b1\u200953 \u00d7 10<jats:sup>3<\/jats:sup> in AL amyloidosis and 138.7\u2009\u00b1\u200953 \u00d7 10<jats:sup>3<\/jats:sup> in SMM patients. Eight (17%) AL amyloidosis and 4 (21%) SMM patients showed a PC CD38\u2010NOS level &lt;100 \u00d7 10<jats:sup>3<\/jats:sup>. In four AL amyloidosis and two SMM patients &lt;10% of PCs had a CD38\u2010NOS \u2265100 \u00d7 10<jats:sup>3<\/jats:sup>. The CD38\u2010NOS identified on bone marrow lymphocytes, monocytes, and granulocytes was two log units below the CD38\u2010NOS on PCs (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). No significant differences in CD38\u2010NOS expression levels on any of the analyzed PC subpopulations in AL amyloidosis and SMM patients were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Levels of CD38 expression affect the isatuximab\u2010mediated ADCC <jats:italic>in vitro<\/jats:italic>. As PCs of patients with AL amyloidosis and SMM do not homogenously express high CD38 our data provide a rationale for assessment of CD38\u2010NOS in patients with PC disorders prior to anti\u2010CD38 treatment. \u00a9 2018 International Clinical Cytometry Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.21636","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:09:55Z","timestamp":1522022995000},"page":"767-776","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma"],"prefix":"10.1002","volume":"94","author":[{"given":"Katharina","family":"Kriegsmann","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Dittrich","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Neuber","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed H. S.","family":"Awwad","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[{"name":"Amyloidosis Center, Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"},{"name":"National Center for Tumor Diseases, University Hospital Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"},{"name":"National Center for Tumor Diseases, University Hospital Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"},{"name":"National Center for Tumor Diseases, University Hospital Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller\u2010Tidow","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[{"name":"Amyloidosis Center, Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology Heidelberg University Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-636357"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.223"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2010.09.002"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3474.3474"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/jco.2014.32.15_suppl.8513","article-title":"Dose\u2010dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)","volume":"32","author":"Lokhorst HM","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12389"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1990-2"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21265"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20547"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.9.1739.1739"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.123"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.42"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11080"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05849.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04260.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/46.8.1221"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-120535"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cair.2005.10.001"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpcy.6"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.8.6.1131-1135.2001"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00137"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21092"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2015.02.001"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22060"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2009.02345.x"},{"key":"e_1_2_6_30_1","first-page":"S48","article-title":"Distribution of CD38 molecules on CD3+ and CD8+ T\u2010lymphocyte in adulthood HIV\u20101\u2010uninfected Thais","volume":"88","author":"Sukwit S","year":"2005","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20106"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.725"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21351"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.21636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.21636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T01:27:45Z","timestamp":1694654865000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.21636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,20]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/cyto.b.21636"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.21636","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,20]]},"assertion":[{"value":"2017-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}